Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Zafgen Inc    ZFGN

ZAFGEN INC (ZFGN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/17/2018 04/18/2018 04/19/2018 04/20/2018 04/23/2018 Date
7.065(c) 6.88(c) 6.85(c) 6.84(c) 6.58(c) Last
235 417 222 573 172 151 166 270 176 866 Volume
+2.54% -2.62% -0.44% -0.15% -3.80% Change
More quotes
Financials (USD)
Sales 2018 1,25 M
EBIT 2018 -61,5 M
Net income 2018 -60,9 M
Finance 2018 126 M
Yield 2018 -
Sales 2019 5,00 M
EBIT 2019 -70,4 M
Net income 2019 -69,4 M
Finance 2019 160 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 50,1x
EV / Sales2019 5,77x
Capitalization 189 M
More Financials
Company
Zafgen, Inc. is a biopharmaceutical company, which is engaged in the development of anti-obesity therapeutics that restores normal fat metabolism and regulatory pathways.Its product: Beloranib, which is under phase 2 clinical development as a treatment for obesity and hyperphagia in Prader-Willi... 
More about the company
Latest news on ZAFGEN INC
03/13ZAFGEN : Reports Fourth Quarter and Full Year 2017 Financial Results
AQ
03/09ZAFGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
03/07Zafgen to Present at Cowen 38th Annual Health Care Conference
GL
03/06ZAFGEN : reports 4Q loss
AQ
03/06ZAFGEN, INC. : Results of Operations and Financial Condition, Financial Statemen..
AQ
03/06Zafgen Reports Fourth Quarter and Full Year 2017 Financial Results; Announces..
GL
03/01Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 F..
GL
03/01ZAFGEN : Patent Issued for Fumigillol Compounds and Methods of Making and Using ..
AQ
02/12ZAFGEN : to Present at the Leerink Partners 7th Annual Global Healthcare Confere..
AQ
02/08Zafgen to Present at the Leerink Partners 7th Annual Global Healthcare Confer..
GL
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/21$ZFGN - Zafgen #ZFGN Stock Rating Lowered by ValuEngine  
04/18Zafgen $ZFGN Expected to Announce Earnings of -$0.53 Per Share  
04/16DOWNSIDE MOMENTUM ALERT: $ZFGN ZAFGEN INC ? TradeIdeas via
1
04/16$ZFGN - Zafgen #ZFGN Upgraded at ValuEngine  
04/16Zafgen $ZFGN Upgraded at ValuEngine  
More tweets
Qtime:127
News from SeekingAlpha
03/15Zafgen (ZFGN) Presents At 38th Annual Cowen And Company Healthcare Conference.. 
03/09Key events next week - healthcare (continued #4) 
03/08Zafgen's Pipeline Takes A Substantial De-Risking Step 
03/06Zafgen's (ZFGN) CEO Jeff Hatfield on Q4 2017 Results - Earnings Call Transcri.. 
03/06Zafgen beats by $0.09 
Chart ZAFGEN INC
Duration : Period :
Zafgen Inc Technical Analysis Chart | ZFGN | US98885E1038 | 4-Traders
Technical analysis trends ZAFGEN INC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 11,0 $
Spread / Average Target 67%
EPS Revisions
Managers
NameTitle
Jeffrey S. Hatfield Chief Executive Officer & Director
Thomas E. Hughes President, Chief Scientific Officer & Director
Peter Barrett Chairman
Patricia L. Allen CFO, Treasurer & Principal Accounting Officer
Dennis D. Kim Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ZAFGEN INC48.05%189
GILEAD SCIENCES3.31%96 094
VERTEX PHARMACEUTICALS5.89%40 153
REGENERON PHARMACEUTICALS-15.95%33 844
GENMAB23.13%12 797
BEIGENE LTD (ADR)71.91%8 998